Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin

This article was originally published in The Pink Sheet Daily

Executive Summary

Tarceva approval comes just three-and-a-half months after application is completed and more than two months ahead of review deadline. Genentech and OSI will begin detailing the non-small cell lung cancer product immediately.

You may also be interested in...



Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says

The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.

Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says

The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.

Tarceva New Rx Share Doubles Since Release Of Failed Iressa Survival Study

New prescription share for Genentech/OSI’s oncologic jumps from about 40% to above 80% following news that AstraZeneca’s Iressa failed to demonstrate a survival benefit. Tarceva sales growth will depend on the ability to differentiate the drug’s profile from that of Iressa, OSI exec says.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel